Welcome to our dedicated page for Integer Hldgs news (Ticker: ITGR), a resource for investors and traders seeking the latest updates and insights on Integer Hldgs stock.
Overview
Integer Holdings Corporation (NYSE: ITGR) is a leading contract development and manufacturing organization (CDMO) renowned for its advanced manufacturing and medical device outsourcing solutions. The company serves a wide spectrum of clients primarily in the medical technology arena, offering comprehensive end-to-end services that encompass research, design, development, and manufacturing of critical medical components and devices.
Core Business and Capabilities
Integer partners with original equipment manufacturers (OEMs) to bring innovative products to market. Its core business segments include:
- Cardio & Vascular: Manufacturing components for cardiovascular devices, providing robust quality and reliability to improve patient outcomes.
- Cardiac Rhythm Management & Neuromodulation: Delivering advanced solutions that support complex therapeutic applications, enhancing precision and performance.
- Other Markets: Serving additional specialized segments with adaptable manufacturing processes and customized solutions.
Through these segments, Integer solidifies its role as a strategic partner for companies seeking to outsource development and manufacturing, ensuring scalability, regulatory compliance, and the efficient transition from design to market-ready products.
Operational Excellence and Innovation
Integer’s operational model is built on a foundation of continuous innovation and quality excellence. The company emphasizes a robust quality management system and streamlined production processes to tackle the inherent challenges of precision manufacturing in the medtech industry. Its state-of-the-art manufacturing facilities and dedicated research and development centers allow for rapid prototyping and seamless integration of new technologies into its production lines.
Strategic Investments and Global Expansion
The company has continuously evolved its global footprint through strategic investments and acquisitions. Significant facility expansions, such as those in Ireland, demonstrate its commitment to enhancing production capacity and technological capabilities. With a presence spanning decades, Integer has built long-standing relationships in critical geographic markets, which further reinforces its ability to serve local and global customer bases efficiently.
Transition to a Pure-Play Medical Technology Company
Historically diversified with a non-medical segment through Electrochem, the company has undertaken strategic realignments. The divestiture of the Electrochem business underscores Integer’s focus on the medtech domain, leveraging its profound expertise in clinical device manufacturing. This transition allows the company to concentrate its resources and capital on further innovation within the medical space, while simultaneously strengthening its balance sheet and operational efficiencies.
Industry Position and Competitive Landscape
Operating in a challenging yet competitive landscape, Integer differentiates itself through its deep expertise in contract development and manufacturing and its robust track record of driving innovation in critical medical markets. Unlike generic manufacturers, Integer combines technical excellence with strategic insight to offer tailored solutions that mitigate product development risks and accelerate time to market. Its comprehensive service model and extensive regulatory experience place it in a favorable position compared to competitors in the CDMO sector.
Value Proposition for Customers and Stakeholders
Integer’s value proposition lies in its ability to leverage extensive industry experience to design, develop, and produce high-quality medical device components with superior reliability. The company’s emphasis on innovation, combined with its strategic investments in technological capabilities and global operational excellence, ensures that it remains a trusted partner for OEMs and healthcare technology companies. By focusing on long-term partnerships, Integer enhances the development process, reduces time-to-market, and helps customers meet regulatory requirements efficiently.
Commitment to Quality and Regulatory Compliance
Quality and regulatory compliance are at the core of Integer’s operations. Investing heavily in quality control measures and process improvements, the company meets rigorous industry standards. This commitment not only enhances patient safety but also ensures that every device and component manufactured aligns with the evolving regulatory landscape of the medical industry.
Research and Development and Technological Advancements
Integer’s integrated approach to research and development fosters an environment where innovative ideas are rapidly translated into high-performance manufacturing solutions. The company’s continuous drive to implement advanced technologies, such as rapid prototyping and scalable production systems, allows it to maintain an edge in a highly technical and precision-driven industry. By bridging the gap between design innovation and full-scale manufacturing, Integer plays a critical role in expediting new therapies and medical solutions.
Conclusion
In summary, Integer Holdings Corporation stands as a pivotal player in the medical device manufacturing ecosystem. With a comprehensive service model, significant global investments, and a dedicated focus on quality and innovation, Integer serves as a critical link in the medical technology supply chain. Its strategic evolution towards a pure-play medtech company further solidifies its position as an expert and trusted partner in delivering complex, high-quality medical devices and components to a diverse range of customers worldwide.
Integer Holdings (NYSE: ITGR), a leading medical device contract development and manufacturing organization, will showcase its innovations at the North American Neuromodulation Society (NANS) Annual Meeting from January 30 to February 1, 2025, in Orlando, Florida. At booth #213, Integer will present its latest advancements in neuromodulation and miniaturized active implantable medical devices (AIMDs).
The company will highlight its Xcellion® Gen 3 Fast Charge (FC) Lithium Ion implantable battery technology, which offers industry-leading battery runtime and can fully recharge in as little as 30 minutes. Integer aims to demonstrate its capabilities as a strategic partner for OEMs, focusing on accelerating and de-risking the path to market for novel implantable medical devices through their expertise in critical implantable technologies.
Integer Holdings (NYSE:ITGR) has announced its schedule for the release of fourth quarter and full year 2024 financial and operational results. The company will disclose the results on Thursday, February 20, 2025, at 7 a.m. Central Time (8 a.m. Eastern Time). Following the release, Integer's management team will host a webcast at 8 a.m. Central Time (9 a.m. Eastern Time) to discuss the results.
Integer Holdings (NYSE: ITGR) has announced that holders of its 2.125% Convertible Senior Notes due 2028 can convert their notes from January 1, 2025, through March 31, 2025. The conversion opportunity arose because the company's stock price exceeded 130% of the conversion price for at least 20 trading days within a 30-day trading period ending December 31, 2024.
The notes are convertible at a rate of 11.4681 shares of common stock per $1,000 principal amount, equivalent to a conversion price of approximately $87.20 per share. Upon conversion, holders will receive cash up to the principal amount, and either cash, shares, or a combination thereof for any remaining conversion value, at Integer's discretion.
Integer Holdings (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The event will take place from December 3-5, 2024, in New York City. President and CEO Joseph Dziedzic will deliver a presentation on Tuesday, December 3, 2024, at 10:30 a.m. EST. The presentation will be available through a live webcast, accessible via the Investor Relations section of Integer's website under 'News & Events' at investor.integer.net.
Integer Holdings (NYSE: ITGR) has completed the sale of its Electrochem business to Ultralife for $50 million in cash. The company will use the proceeds to reduce its outstanding debt. This divestiture transforms Integer into a pure-play medical technology company, focusing exclusively on its medical device contract development and manufacturing operations (CDMO). The strategic move aims to enable Integer to deploy additional capital in high-growth medtech markets.
Integer Holdings (NYSE: ITGR) announced key leadership changes effective Q1 2025. Payman Khales, current President of Cardio & Vascular, will become Chief Operating Officer, overseeing both product categories along with Global Operations and Manufacturing Strategy. Andrew Senn will succeed Khales as President of Cardio & Vascular. Under Khales' leadership since 2018, the Cardio & Vascular business achieved above-market growth. Senn brings 18 years of experience at Integer and extensive industry knowledge from various leadership roles.
Integer Holdings (NYSE:ITGR) reported strong Q3 2024 results with sales increasing 9% to $431 million, including 4% organic growth. GAAP income from continuing operations rose 29% to $36 million, while non-GAAP adjusted net income grew 14% to $50 million. The company raised its 2024 outlook, expecting sales growth of 10-11% with organic growth of 7-8%. The planned sale of Electrochem business for $50 million remains on track. Year-to-date sales increased 10% to $1.267 billion, with adjusted EBITDA up 22% to $266 million. Total debt stood at $1.079 billion with a leverage ratio of 3.0x adjusted EBITDA.
Integer Holdings (NYSE: ITGR) has announced that holders of its 2.125% Convertible Senior Notes due 2028 can now convert their notes into cash and/or shares of the company's common stock. The conversion period is from October 1, 2024, to December 31, 2024. This option became available because the company's stock price exceeded 130% of the conversion price for at least 20 trading days in the 30-day period ending September 30, 2024.
The notes are convertible at a rate of 11.4681 shares of common stock per $1,000 principal amount, equivalent to a conversion price of approximately $87.20 per share. Integer will pay cash up to the principal amount of the notes converted, with any excess paid in cash, shares, or a combination at the company's discretion. Detailed conversion procedures have been provided to noteholders through The Depository Trust Company and Wilmington Trust, National Association.
Integer Holdings (NYSE: ITGR) has announced an agreement to divest its Electrochem business to Ultralife (NASDAQ: ULBI) for $50 million in cash. This divestiture transforms Integer into a pure-play medical technology company. The transaction is expected to close by the end of October, subject to customary working capital adjustments.
Key points:
- Electrochem focuses on non-medical applications for energy, military, and environmental sectors
- Integer will report Electrochem's results as part of discontinued operations
- Proceeds will be used to pay down debt and for general corporate purposes
- The transaction is expected to be neutral to EPS
- 2024 full-year guidance for the non-medical segment included $36 million in sales and $5 million in Adjusted EBITDA
Integer Holdings (NYSE:ITGR) has announced its schedule for the release of third quarter 2024 financial and operational results. The company plans to disclose these results on Thursday, October 24, 2024, at 7 a.m. Central Time (CT) / 8 a.m. Eastern Time (ET).
Following the release, Integer's management will host a webcast at 8 a.m. CT / 9 a.m. ET to discuss the quarterly results. This announcement provides investors and analysts with a clear timeline for accessing and analyzing the company's latest financial performance data.
FAQ
What is the current stock price of Integer Hldgs (ITGR)?
What is the market cap of Integer Hldgs (ITGR)?
What is the core business of Integer Holdings Corporation?
How does Integer generate its revenue?
What distinguishes Integer from its competitors?
What are the primary product segments served by Integer?
What role does research and development play at Integer?
How has Integer's strategic focus evolved?
Why is quality and regulatory compliance important to Integer?
How does Integer support its global customer base?
